Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 25 04:00PM ET
3.62
Dollar change
+0.31
Percentage change
9.37
%
IndexRUT P/E- EPS (ttm)-4.39 Insider Own56.64% Shs Outstand43.59M Perf Week-1.90%
Market Cap157.80M Forward P/E- EPS next Y-1.18 Insider Trans-2.54% Shs Float18.90M Perf Month60.18%
Income-69.24M PEG- EPS next Q-0.26 Inst Own47.93% Short Float2.27% Perf Quarter0.56%
Sales0.00M P/S- EPS this Y50.56% Inst Trans2.60% Short Ratio1.47 Perf Half Y-29.30%
Book/sh1.36 P/B2.66 EPS next Y-13.87% ROA- Short Interest0.43M Perf Year-53.17%
Cash/sh2.29 P/C1.58 EPS next 5Y- ROE- 52W Range2.00 - 14.00 Perf YTD-22.48%
Dividend Est.- P/FCF- EPS past 5Y- ROI-116.71% 52W High-74.14% Beta0.38
Dividend TTM- Quick Ratio4.97 Sales past 5Y0.00% Gross Margin- 52W Low81.00% ATR (14)0.39
Dividend Ex-Date- Current Ratio4.97 EPS Y/Y TTM-2148.09% Oper. Margin0.00% RSI (14)59.59 Volatility13.38% 12.46%
Employees15 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.33
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-641.35% Payout- Rel Volume1.16 Prev Close3.31
Sales Surprise- EPS Surprise40.57% Sales Q/Q- EarningsMar 28 BMO Avg Volume292.38K Price3.62
SMA2020.25% SMA5012.40% SMA200-25.46% Trades Volume338,697 Change9.37%
Date Action Analyst Rating Change Price Target Change
Oct-10-23Initiated Ladenburg Thalmann Buy $10
Aug-25-23Initiated Oppenheimer Outperform $17
Jun-22-23Initiated Guggenheim Buy $20
Jun-14-23Initiated Chardan Capital Markets Buy $14
May-24-23Initiated Raymond James Strong Buy $20
Apr-25-24 02:18AM
Apr-18-24 09:22AM
Apr-08-24 06:00AM
Mar-28-24 11:54AM
06:00AM
06:00AM Loading…
Mar-04-24 06:00AM
Feb-02-24 06:00AM
Jan-08-24 06:00AM
Jan-03-24 06:00AM
Dec-04-23 06:00AM
Nov-14-23 06:00AM
Nov-13-23 06:30AM
Sep-12-23 05:00AM
Sep-05-23 08:55PM
Aug-25-23 09:42AM
07:00AM Loading…
Aug-14-23 07:00AM
Jun-23-23 06:30AM
Jun-06-23 06:34AM
04:00AM
Jun-01-23 10:20AM
Apr-27-23 07:39AM
Apr-14-23 05:00AM
Mar-27-23 09:35AM
Mar-21-23 06:13AM
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sidhu SomeitDirectorApr 22 '24Buy3.131,186,9013,715,0001,186,901Apr 24 06:51 PM
Munshi AmitDirectorApr 22 '24Buy3.13159,744499,999777,384Apr 24 06:52 PM
Howell MichaelSee RemarksApr 22 '24Buy3.137,98724,9997,987Apr 24 06:54 PM
Nistala KiranExecutive Vice PresidentApr 22 '24Buy3.133,19510,0003,195Apr 24 06:53 PM
Thiara ParvinderDirectorDec 12 '23Sale4.002,000,0008,000,0004,801,633Dec 14 03:35 PM
Munshi AmitDirectorJun 05 '23Buy4.25117,647500,000617,640Jun 05 07:15 PM